Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS72GN)

• Drug Name: AMG 172 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Renal cell carcinoma	2C90	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMS72GN

Molecule-Related Drug Atlas

Drug(s) Targeting CD70 antigen (CD27-L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-74494550	DM3ICO6	Myelodysplastic syndrome	2A37	Phase 2	[3]
4SCAR19 and 4SCAR70	DMKC8F9	B-cell lymphoma	2A86	Phase 1/2	[4]
MDX-1203	DM0RIQF	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
MDX-1411	DM3402P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
BMS-936561	DMYIBFM	Haematological malignancy	2B33.Y	Phase 1	[7]
SGN-70	DMXA7W9	Autoimmune diabetes	5A10	Phase 1	[8]
SGN-CD70A	DMMJ1PO	Non-hodgkin lymphoma	2B33.5	Phase 1	[9]
Anti-hCD70 CAR transduced PBL	DMK4GIS	Ovarian cancer	2C73	Phase 1	[10]
SEA-CD70	DMX94YF	Acute myeloid leukaemia	2A60	Phase 1	[11]
CTX130	DM926CH	T-cell lymphoma	2A90	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD70 antigen (CD27-L)	TTNCIE0	CD70_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT01497821) AMG 172 First in Human Study in Patients With Kidney Cancer. U.S. National Institutes of Health.
• [2] National Cancer Institute Drug Dictionary (drug id 721679).
• [3] Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467.
• [4] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [5] J Clin Oncol 32:5s, 2014 (suppl; abstr 2558).
• [6] Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3.
• [7] Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106.
• [8] 2011 Pipeline of Seattle Genetics.
• [9] SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647.
• [10] ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
• [11] Clinical pipeline report, company report or official report of Seagen.
• [12] Clinical pipeline report, company report or official report of CRISPR Therapeutics.